High-risk features, duration of targeted therapy prior to allogeneic HCT, and time to event. (A) Duration of each targeted therapy is denoted in pink (ibrutinib), green (CD19 CAR-T), dark blue (idelalisib), and light blue (venetoclax). Of note, time between targeted therapies is not reflected in the duration of targeted therapy. In the center, boxes in red indicate subjects with IGHV unmutated (UM), del(17p), complex abnormalities (≥5), or Richter transformation. Boxes in blue indicate no mutation or no Richter transformation. Boxes in gray indicate missing information. Tot no. of prior tx denotes the total number of targeted and chemoimmunotherapies received prior to alloHCT. No. of CIT denotes the total number of chemoimmunotherapies prior to targeted therapy. Disease status denotes complete remission (C), partial remission (P), relapse (R), or induction failure (I) at alloHCT. (B) The blue horizontal bars indicate time to death or last seen alive with the indication of relapse and post-HCT therapy.